Rigas Austrumu kliniska universitates slimnica SIA
- Address
- Hipokrata Iela 4, 1079 Riga, Latvia
Rigas Austrumu Kliniska Universitates Slimnica - Advanced Clinical Research Center
Rigas Austrumu Kliniska Universitates Slimnica serves as a leading clinical research institution in Latvia, conducting sophisticated Phase 2 and Phase 3 trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology, autoimmune disorders, and cardiovascular medicine, contributing to the development of innovative therapeutic approaches for complex medical conditions.
- Oncology research including non-small cell lung cancer, glioblastoma multiforme, bladder cancer, and gastric/gastroesophageal junction adenocarcinoma
- Autoimmune and inflammatory diseases with focus on psoriatic arthritis, relapsing multiple sclerosis, and thyroid eye disease
- Cardiovascular and metabolic conditions including atrial fibrillation, heart failure with reduced ejection fraction, and atherosclerotic cardiovascular disease
- Infectious diseases and ophthalmologic disorders including complicated urinary tract infections and neovascular age-related macular degeneration
The center's research portfolio encompasses cutting-edge studies evaluating novel immunotherapies, biologics, and targeted therapies, including investigations of pembrolizumab combinations, monoclonal antibodies, and gene therapies. With extensive experience in respiratory conditions such as bronchiectasis and expertise in advanced antimicrobial resistance studies, the institution plays a crucial role in advancing treatment options for patients with carbapenem-resistant infections and other challenging medical conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rigas Austrumu kliniska universitates slimnica SIA
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Milvexian | 3 | Unknown | 2023-08-04 | 2023-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.